Recalibrating sham-relative superiority thresholds in BPH device trials

Area of Science:

• Urology
• Medical Device Evaluation
• Clinical Trial Methodology

Background:

• Minimally invasive surgical therapies for benign prostatic hyperplasia (BPH) are increasingly evaluated using sham-controlled trials.
• Early changes in International Prostate Symptom Score (IPSS) and sham-relative superiority thresholds are common primary efficacy endpoints.

Purpose of the Study:

• To examine the impact of strong sham responses on the interpretation of BPH device efficacy.
• To discuss the statistical, clinical, and regulatory implications of using sham-relative superiority margins.

Main Methods:

• Methodological perspective on statistical frameworks for BPH device trials.
• Emphasis on 3-month IPSS change as a primary endpoint.
• Contextualization of early symptom changes against longer-term outcomes like durability and retreatment.

Main Results:

• Sham-relative testing creates a moving efficacy threshold that increases with sham improvement.
• Strong sham effects may indicate smaller device-specific benefits rather than flawed trial design.
• Three-month endpoints offer early signals but may not reliably predict durable success.

Conclusions:

• Rigorous sham-controlled designs remain essential for BPH device trials.
• Efficacy assessment should incorporate durable outcomes, clinically meaningful differences, and patient-reported benefits.
• Avoid overreliance on transient early symptom score changes for trial success.